Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis for pre-seasonal therapy

Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis for pre-seasonal therapy - Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis for pre-seasonal therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030789

Enrollment

Registered

2018-01-16

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal allergic conjunctivitis

Interventions

Epinastine hydrochloride ophthalmic solution, apply 1 drop a time, 4 times daily, for 12 weeks Artificial tear, apply 2-3 drops a time, 5-6 times daily, for first 4 weeks and epinastine hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient diagnosed with seasonal allergic conjunctivitis in the past Positive result for cedar pollen antigen in an antigen-specific IgE examination in serum

Exclusion criteria

Exclusion criteria: Patient under immunotherapy (including hyposensitization therapy and allassotherapy) Has history of allergy to the ingredients of the study drug and clinical reagents Patient who the investigator considers ineligible for enrolment

Design outcomes

Primary

Measure	Time frame
Change in values of the following After 4weeks and 12weeks therapy -Expression levels of chemical mediator receptor mRNA on conjunctival epithelial cells -Levels of chemical mediator in tears	—

Secondary

Measure	Time frame
Change in values of the following After 4weeks and 12weeks therapy -Subjective symptom scores -Objective finding scores Adverse event	—

Countries

Japan

Contacts

Public ContactYoshihiro Sugio

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group, Development Management Department, Japan Business

clinical@santen.co.jp06-4802-9604

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026